The Oncolytic Virus Immunotherapy Market To Grow On An Unparalleled Note In The Next 10 Years

1
Oncolytic Virus Immunotherapy Market
Report Id PMRREP15262 Category Life Science
Healthcare
2
About Persistence Market Research
Customized Research
Persistence Market Research(Persistence Market
Research) is a premier provider of syndicated
research reports, custom research reports, and
consulting services. We deliver a complete
packaged solution, which combines current market
intelligence, statistical anecdotes, technology
inputs, valuable growth insights, aerial view of
the competitive framework, and future market
trends. We provide research services at a global
as well as regional level key regions include
GCC, ASEAN, and BRIC. Our offerings cover a broad
spectrum of industries including Chemicals,
Materials, Energy, Technology, Healthcare, and
Retail. We have a global presence with delivery
centers across India specializing in providing
global research reports and country research
reports. Persistence Market Research is
headquartered out of London, U.K., with a
state-of-the-art delivery center located in Pune,
India. We combine our knowledge and learning from
every corner of the world to distill it to one
thing the perfect solution for our client.
Syndicated Research
Investment Research
Social Media Research
Research Capabilities
Sector Coverage

• Customized Research
• Syndicated Research
• Investment Research
• Social Media Research

• Automotive and Transportation
• Electronics, Semiconductor, and ICT
• Retail and Consumer Products
• Industrial Automation and Equipment

• Chemicals Materials
• Food and Beverages
• Services and Utilities
• Energy, Mining, Oil, and Gas

Subscription Information
For detailed subscription information please
contact Website www.persistencemarketresearch.co
m For sales queries or new topics email us on
sales_at_persistencemarketresearch.com
3
The Oncolytic Virus Immunotherapy Market To Grow
On An Unparalleled Note In The Next 10 Years

• The new study report by Persistence Market
  Research (PMR) reveals that the oncolytic virus
  immunotherapy market value is all set to
  reach US 67 Mn, by 2019-end. As per the PMRs
  report, the oncolytic virus immunotherapy
  market is estimated to grow at a CAGR of
  12 over the period of assessment, 2019-2029.
• Increasing adoption of adjuvant therapy in
  developed economies has been fueling the demand
  for new treatments such as oncolytic virus
  immunotherapy. For instance, the launch of first
  FDA approved oncolytic virus, IMLYGIC
  (talimogene laherparepvec) by the leading
  pharmaceutical manufacturer Amgen has offered
  oncologists and patients a wider and more
  targeted treatment approach for overcoming
  cancer. Amgens IMLYGIC remains the only FDA
  approved oncolytic virus immunotherapy drug that
  is prescribed for melanoma cancer.

Get Sample Copy of Report _at_ https//www.persistenc
emarketresearch.com/samples/15262 
4
Increasing Immunotherapy Research Will Offer New
Growth Prospects
According to the PMR study, increasing importance
of RD in oncology medicines and immunotherapies
for cancers such as colorectal, lung, multiple
myeloma, prostate, and melanoma is expected to
create immense growth opportunities for the
oncolytic virus immunotherapy market. Besides
this, collaborations among the key players in the
pharmaceutical industry, funding programs and
reimbursement policies to meet the unmet
diagnostic and treatment needs of the patients
suffering from life-threatening diseases such as
cancer are also expected to fuel the growth of
the oncolytic virus immunotherapy
market. Growing interest of biopharmaceutical
industries in the development of biologics for
various cancers, will further expand the pipeline
for the treatment of cancer. Various major
players are concentrating on the research for the
available treatment and development of specific
oncolytic virus for cancer, which will boost the
market for oncolytic virus immunotherapy during
the forecast period.
Access Full Report _at_ https//www.persistencemarket
research.com/checkout/15262
5
(No Transcript)